Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8297342 | 0.79 | — | — | |
| SCHEMBL3293088 | 0.78 | ALDH1A1 (0.63) | ALDH1A1GLAKDM4ETSHRTDP1 | |
| SCHEMBL11645181 | 0.76 | ALDH1A1 (0.61) | ALDH1A1GLAKDM4ETSHRTDP1 | |
| SCHEMBL28282461 | 0.76 | ALDH1A1 (1.00) | ALDH1A1GLAKDM4ETSHRTDP1 | |
| SCHEMBL28651135 | 0.76 | ALDH1A1 (0.61) | ALDH1A1GLAKDM4ETSHRTDP1 | |
| SCHEMBL10651010 | 0.76 | ALDH1A1 (0.61) | ALDH1A1GLAKDM4ETSHRTDP1 | |
| SCHEMBL28302547 | 0.76 | ALDH1A1 (0.56) | ALDH1A1GLAKDM4ETSHRGRIA1 | |
| SCHEMBL11325306 | 0.76 | ALDH1A1 (0.56) | ALDH1A1GLAKDM4ETDP1CYP3A4 | |
| SCHEMBL17347283 | 0.73 | ALDH1A1 (0.58) | ALDH1A1GLAKDM4ECYP3A4GRIA1 | |
| SCHEMBL28498547 | 0.73 | ALDH1A1 (0.53) | ALDH1A1GLAKDM4ETSHRGRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024125626-A1 | NITROGENOUS COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024083208-A1 | KIF18A PROTEIN INHIBITOR | 杭州邦顺制药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-117917405-A | KIF18A protein inhibitors | 杭州邦顺制药有限公司 | 2024-04-23 | — | — | CN | disclosed |
| US-9987261-B2 | Substituted diazaspiroalkanes as androgen receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170014399-A1 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-01-19 | — | — | US | disclosed |
| WO-2017001733-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2017-01-05 | — | — | WO | disclosed |
| US-9388159-B2 | Substituted diazaspiroalkanes as androgen receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-12 | — | — | US | disclosed |
| EP-2303867-B1 | PYRAZINONE MODULATOR OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140309262-A1 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2014-10-16 | — | — | US | disclosed |
| US-8802689-B2 | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-12 | — | — | US | disclosed |
| US-20110166160-A1 | Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity | BRISTOL-MYERS SQUIBB COMPANY | 2011-07-07 | — | — | US | disclosed |
| US-7932256-B2 | (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932256-B2 | (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20110003839-A1 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010014280-A1 | PYRAZINONE MODULATOR OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029684-A1 | Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| US-20100029684-A1 | Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| WO-1999057604-A1 | NON-LINEAR OPTICAL MATERIALS | UNIVERSITY OF STRATHCLYDE (GB) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029684-A1 | Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity | CRH, CRHR1, CRHR2 | ALDH1A1 2086/4885GLA 4825/4885KDM4E 3550/4885 |
| US-20110166160-A1 | Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity | CRH, CRHR1, CRHR2 | ALDH1A1 2086/4885GLA 4825/4885KDM4E 3550/4885 |
| US-20140309262-A1 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | AR, ESRRA, NR5A1 | ALDH1A1 1411/4885GLA 863/4885KDM4E 3283/4885 |
| US-20170014399-A1 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | AR, ESRRA, NR5A1 | ALDH1A1 1411/4885GLA 863/4885KDM4E 3283/4885 |
| US-20110003839-A1 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | AR, NR5A1, SHBG | ALDH1A1 991/4885GLA 1410/4885KDM4E 2986/4885 |
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | ALDH1A1 786/4885GLA 4195/4885KDM4E 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.